Background {#Sec1}
==========

Hepatitis C virus (HCV) infection is a widespread and chronic disease that is most prevalent among people who inject drugs (PWID) \[[@CR1], [@CR2]\], and which also disproportionately impacts racial and ethnic minorities \[[@CR3]--[@CR5]\], veterans \[[@CR6]\], those who are incarcerated \[[@CR7]--[@CR9]\], the poor \[[@CR10], [@CR11]\], and unstably housed persons \[[@CR12], [@CR13]\]. A large number and proportion of HIV-infected patients are also co-infected with HCV \[[@CR14]\]. Household-based surveillance puts estimates of the number of adult Americans ever infected with HCV at 3.6 million persons, and 2.7 million persons with chronic HCV \[[@CR10]\]. However, since these surveys exclude the majority of high-risk populations, including incarcerated and homeless persons, the actual number is likely much higher, with an estimated 3.5 million current chronic infections (range 2.7 to 4.7 million) \[[@CR15]\]. While a new generation of antiviral drugs (direct acting antivirals or DAAs) is transforming clinical outcomes, access remains a challenge, especially for these most affected groups, as a result of economic and other barriers, including low rates of screening, diagnosis and linkage to care \[[@CR3]\]. The lack of data regarding HCV in these populations adds to the uncertainty regarding the burden of HCV infection and the potential impact DAAs could have on population health and even potential eradication \[[@CR16]\].

Testing and identifying those with HCV are the most significant first steps needed to engage infected patients in care and provide access to curative treatments. Risk-based HCV testing guidance issued by the Centers for Disease Control and Prevention (CDC) in 1998, and the U.S. Public Health Service and Infectious Diseases Society of America in 1999 \[[@CR17], [@CR18]\], was updated in 2012 by the CDC to include those born between 1945 and 1965 (the "baby boomers") \[[@CR19]\]. It was endorsed by the United States Preventive Services Task Force in 2013 after research showed this age group accounts for a large proportion (75%) of chronic HCV infections diagnosed and have elevated risk of mortality \[[@CR20], [@CR21]\]. While several studies have noted that HCV infection is elevated in homeless or unstably housed adult populations women are generally underrepresented in these studies \[[@CR12], [@CR13]\]. The purpose of this study was to determine the prevalence and correlates of HCV exposure in a well-characterized cohort of homeless and marginally housed women, and estimate the proportion of women with undiagnosed HCV exposure.

Methods {#Sec2}
=======

Participants and setting {#Sec3}
------------------------

This study analyzed cross-sectional data from "Shelter, Health and Drug Outcomes among Women" (SHADOW), a prospective cohort study of homeless and unstably housed women in San Francisco \[[@CR22]\]. Recruitment and enrollment occurred between June 2008 and August 2010. Using methods developed by Burman and Koegel \[[@CR23]\], designed to recruit a representative sample of homeless individuals, women were systematically approached at free meal programs, homeless shelters, and low-cost single room occupancy (SRO) hotels selected with probability proportionate to the number of individuals served, and invited to participate in baseline screening at the study venue located in the Tenderloin neighborhood in downtown San Francisco. HIV-infected women were oversampled to meet the primary aims of the SHADOW study \[[@CR22], [@CR24]\]. Study inclusion criteria included female sex (biological), age ≥18 years, and a lifetime history of housing instability (slept in a public place, a shelter, or stayed with a series other people because they had no other place to sleep \["couch-surfed"\]). Private interviews were conducted to collect data on demographic and social factors as shown in detail in the study survey (See Additional file [1](#MOESM1){ref-type="media"}). Sensitive questions regarding drug use and sex were obtained via audio computer-assisted self-interviews. Participants were interviewed every 6 months and reimbursed \$15 for each interview completed. The study protocol and procedures were reviewed and approved by the Institutional Review Board at the University of California, San Francisco (UCSF). All participants completed a signed informed consent process.

Measures {#Sec4}
--------

Data for the current analysis were collected during a cross-sectional sub-study that screened for co-infections including HCV, herpes simplex virus type 2 (HSV-2) and Trichomonas vaginalis, conducted between April and October, 2010. *Serologic testing:* The primary outcome for the current study was HCV infection exposure, including monoinfection and coinfection with HIV. Cohort participants were tested for anti-HCV using an enzyme immunoassay (EIA) test (EIA-3; OrthoClinical Diagnostics, Raritan, NJ) with a signal to cut off \>8 indicating a positive result (Quest Diagnostics, San Francisco, CA). The test has 100% sensitivity and 99.95% specificity for detection of anti-HCV \[[@CR25]\]. HIV status was determined using a point of care test (OraQuick®; OraSure Technologies, Bethlehem, Pennsylvania) and confirmatory Western Blot if positive. All women participating in the study were referred for care and additional evaluation if they had positive results for any infections. Specifically with respect to HCV, women were informed that that this was a screening test and that confirmatory testing would be needed to determine whether they had chronic infection.

*Exposures of interest:* Women were asked if they had ever been tested for a sexually transmitted infection (STI). Those who answered 'yes', were asked to indicate if they had ever tested for HCV, and if so what year they were tested. Women who answered 'no' to testing for any sexually transmitted infection (STI) or no to a previous positive anti-HCV were judged to be unaware of their HCV status and categorized as not having had a previous positive test. Biological, social and behavioral health factors known to be more prevalent among disadvantaged women compared to women in the general population were used in these analyses and included: unmet subsistence needs (insufficient access to food, clothing, a restroom, a place to wash or a place to sleep) \[[@CR26]\]; instrumental social support (someone who would give money or a place to sleep) \[[@CR27]\]; sexual orientation (heterosexual, bisexual or lesbian); and drug use, including injection drug use, and any use of crack cocaine, heroin or methamphetamine. Alcohol use was categorized as 'at-risk' if women reported drinking \>1 drink/day \[[@CR28]\]) and binge drinking (\>4 drinks at one time for women) \[[@CR29]\]. Multiple mental health measures were directly assessed by the computerized Diagnostic Interview Schedule (DIS)-IV, which uses DSM-IV criteria \[[@CR30]\], including depression, and psychiatric disorders (anxiety, psychotic, mood, pain, somatization, substance use, dementia, and post-traumatic stress disorders) \[[@CR30], [@CR31]\]. Psychiatric diagnoses were grouped, and analyzed based on the number of diagnoses due to interactions between diagnoses among persons with co-occurring conditions \[[@CR32]\].

Analyses {#Sec5}
--------

Standard descriptive statistics were used to analyze socio-demographic, behavioral and clinical parameters by anti-HCV status, including monoinfection and HCV/HIV coinfection. Bivariate comparisons were conducted using the Kruskal-Wallis test for nonparametric continuous variables and Pearson chi-square (χ^2^) test or Fisher exact test (for cell sizes ≤5) for categorical variables. Odds ratios (OR) and 95% confidence intervals (CI) determined the magnitude of effect as well as the amount of variability in each estimate. Inferences were based on simultaneous adjustment for exposure variables using multiple logistic regression. To assess independent associations with HCV exposure, a backward stepwise approach was employed in which bivariate predictors with a *p*-value of 0.25 or less were included in the initial multivariable model, and variables were eliminated until all remaining parameter estimates had *p*-values less than 0.05 \[[@CR33]\]. We used a *p*-value cut-off point of 0.25 for variable selection over more conservative levels such as 0.05 in order to maximize potential to identify important variables \[[@CR34]\]. Multi-collinearity between explanatory variables was examined and effect modification considered. Adjusted Odds Ratios (AOR) were computed to examine excess risk in association with variables found to be independently associated with anti-HCV positivity.

Results {#Sec6}
=======

Over 90% of eligible women agreed to participate in the cohort study, resulting in a sample of 300. Of those, 246 (82%) had concomitant interview and anti-HCV testing data. A total of 113 (45.9%) women had detectable anti-HCV, of whom 61.1% were HIV coinfected. Consistent with the recruitment strategy, just over half of the sample (*n* = 127; 51.6%) was HIV-infected. There were no significant differences between participants who did and did not have available data for the current analysis with regard to socioeconomic, sexual and drug use variables (*p* \> 0.05). Median age in the total group was 48 years (Interquartile Range \[IQR\] 43, 54), but this varied significantly by HIV and HCV infection or coinfection group. Seventy-two percent of the sample corresponded to the 'baby-boomer' cohort (born between 1945 and 1965); median birth year for women who were HIV/HCV coinfected and HCV monoinfected was 1958, for HIV monoinfected women it was 1964, and uninfected women, 1962. Table [1](#Tab1){ref-type="table"} shows sociodemographic and health characteristics and recent risk exposures (in previous 6 months) of the study sample and associations with HCV and HIV infection and coinfection outcomes. More than half (54%) of women met diagnostic criteria for depression, recent crack use was reported by 46%, and 19% reported recent injection drug use (IDU). In addition to age, significant differences were found by education, recent transactional sex, having seen a primary care provider recently, number of psychiatric diagnoses, recent heroin use, injection drug use and HCV and HIV outcomes in bivariate analyses (Table [1](#Tab1){ref-type="table"}). No differences were found in reported binge drinking, or marijuana use between groups.Table 1Prevalence of selected characteristics among all participants and associations with anti-HCV, HIV and HIV/HCV infection statusVariablePrevalence of characteristic^b^(*N* = 246)HIV/HCV coinfected (*N* = 69)HCV mono-infected (*N* = 44)HIV mono-infected (*N* = 58)Non-infected (*N* = 75)*N*(%)*N*(%)*N*(%)*N*(%)*N*(%)*p*-value^a^\# Completed surveys246(100)69(28)44(18)58(24)75(30)Reported a previous positive test for HCV^b^ Yes88(36)51(75)29(67)6(10)2(3)*\<.0001* No/Skipped155(64)17(25)14(33)52(90)72(97)Race Nonwhite176(72)48(27)28(16)44(25)56(32)*0.5* White70(28)21(30)16(23)14(20)19(27)Age, median (IQR)48(42--54)50(46--54)50(46--54)45(40--51)47(41--54)*0.0092*Birth cohort After 196569(28)10(14)10(14)25(36)24(35)*0.0029* 1965 and earlier177(72)59(33)34(19)33(19)51(29)High school graduate No86(35)37(43)15(17)21(24)13(15)*0.0001* Yes160(65)32(20)29(18)37(23)62(39)Sexual Orientation Heterosexual190(77)52(27)31(16)49(26)58(31)*0.39* Lesbian/Bi-sexual56(23)17(30)13(23)9(16)17(30)Recent income (past 6 months): \$, median (IQR)934(812--1149)908(800--1025)973(800--1200)935(845--1175)949(659--1375)*0.41*Physical Health Score, median (IQR)39(30--48)36(29--45)38(29--49)37(30--47)42(32--52)*0.13*Mental Health Score, median (IQR)43(34--55)43(36--53)43(32--57)43(32--53)45(34--55)*0.9*Primary care visit in last 6 months Yes203(83)64(32)31(15)55(27)53(26)*\<.0001* No43(17)5(12)13(30)3(7)22(51)Current depression Yes129(54)30(23)21(16)35(27)43(33)*0.11* No108(46)38(35)21(19)20(19)29(27)No. of psychiatric diagnoses, median (IQR)7(4--10)9(5--13)9(5--11)7(4--9)5(3--9)*0.0005Risk exposures in the past 6 months:*Incarcerated Yes28(11)10(36)2(7)7(25)9(32)*0.42* No218(89)59(27)42(19)51(23)66(30)Slept in a public place or homeless shelter Yes59(24)14(24)11(19)12(20)22(37)*0.56* No187(76)55(29)33(18)46(25)53(28)Unmet subsistence needs Yes104(42)31(30)18(17)25(24)30(29)*0.94* No142(58)38(27)26(18)33(23)45(32)Sex for money Yes23(9)1(4)10(43)8(35)4(17)*0.0005* No223(91)68(30)34(15)50(22)71(32)Sex for drugs Yes15(6)1(7)4(27)6(40)4(27)*0.12* No231(94)68(29)40(17)52(23)71(31)Heavy drinking Yes50(20)16(32)11(22)11(22)12(24)*0.6* No196(80)53(27)33(17)47(24)63(32)Binge drinking Yes96(39)31(32)18(19)19(20)28(29)*0.55* No150(61)38(25)26(17)39(26)47(31)Injection drug use Yes47(19)18(38)14(30)7(15)8(17)*0.0071* No199(81)51(26)30(15)51(26)67(34)Crack use Yes114(46)38(33)22(19)25(22)29(25)*0.22* No132(54)31(23)22(17)33(25)46(35)Cocaine use Yes30(12)10(33)5(17)5(17)10(33)*0.76* No216(88)59(27)39(18)53(25)65(30)Methamphetamine use Yes51(21)12(24)11(22)9(18)19(37)*0.41* No195(79)57(29)33(17)49(25)56(29)Heroin use Yes31(13)13(42)10(32)4(13)4(13)*0.0074* No215(87)56(26)34(16)54(25)71(33)^a^ *P* values for medians were obtained using the Kruskal-Wallis test; Categorical variable *p* values use either the Chi-square test (if all cell counts are greater than 5), or Fisher's Exact test (if one or more cell counts less than or equal to 5)^b^Percentages are column percents

Table [2](#Tab2){ref-type="table"} shows unadjusted correlates and a final multivariable logistic model of factors independently associated with HCV exposure. In the final model, birth cohort, less than high school education, number of psychiatric diagnoses, and a history of IDU were associated with elevated odds of anti-HCV positivity. Women who were born before 1965, and with a history of IDU had four times higher odds of HCV exposure. In addition, odds increased 12% for each additional psychiatric diagnosis, but current depression was associated with lower odds of HCV exposure.Table 2Social and Behavioral Correlates of anti-HCV positive status among homeless and unstably housed biological women living in San Francisco, CA (*N* = 237)UnadjustedAdjusted^a^OR (95% CI)OR (95% CI)Non-white Race0.68 (0.39--1.18)Age (per year increase)1.05 (1.02--1.08) \*\*\*Birth cohort  *After 1965*1  *1965 and earlier*2.71 (1.49--4.93) \*\*\*3.94 (1.88--8.26) \*\*\*Less than high school graduate (vs high school graduate)2.48 (1.45--4.25) \*\*\*2.56 (1.36--4.82) \*\*\*Sexual Orientation  *Heterosexual*1  *Homo-/Bi-sexual*1.49 (0.82--2.71)Recent income (per \$100 increase)0.97 (0.93--1.01)Physical Health Score (per 1 point increase)0.98 (0.96--1) \*Mental Health Score (per 1 point increase)1.01 (0.99--1.03)Current Depression0.54 (0.32--0.91) \*\*0.24 (0.12--0.48) \*\*\*No. of psychiatric diagnoses (per 1+ increase)1.12 (1.06--1.18) \*\*\*1.16 (1.08--1.25) \*\*\*Risk exposures in the past 6 months: Incarcerated (yes vs. no)0.87 (0.39--1.92) Slept in a public place or homeless shelter (yes vs. no)0.83 (0.46--1.49) Unmet subsistence needs (yes vs. no)1.09 (0.65--1.8) Sex for money (yes vs. no)1.09 (0.46--2.57) Sex for drugs (yes vs. no)0.57 (0.15--1.9) Heavy drinking (yes vs. no)1.5 (0.81--2.8) Injection drug use (yes vs. no)3.11 (1.58--6.11) \*\*\*4.0 (1.68--9.55) \*\*\* Crack use (yes vs. no)1.66 (1--2.75) \* Cocaine use (yes vs. no)1.2 (0.56--2.59) Methamphetamine use (yes vs. no)0.96 (0.52--1.78) Heroin use (yes vs. no)3.99 (1.71--9.33) \*\*\*^a^Adjusted for birth cohort, education, current depression, number of psychiatric diagnoses, and injection drug use (each adjusted for the others)*\* p \< .1\*\* p \< .05\*\*\* p \< .01*

Among the 246 women in the sample, 180 (73.2%) reported prior STI testing, and 88 (35.8%) women reported a previous positive HCV test. Among all women with positive serological results and who responded to questions regarding previous testing (*n* = 111 of 113 total positives), over a quarter (27.9%) reported a prior negative test, indicating almost one-third were unaware of their status. Twenty-five percent (17/68) of HIV/HCV coinfected women were not aware of their positive anti-HCV status, compared to 32.6% (14/43) of those with HCV monoinfection results (*p* = 0.4). Among women who tested anti-HCV negative in the study, including 58 with HIV infection and 74 uninfected women, almost all had no previous HCV positive result: 89.7 and 97.3%, respectively. Women who were anti-HCV positive and reported no previous test or a negative test were significantly (*p* \< 0.02) older (median age: 52 years \[IQR: 48, 56\]) than those who reported a previous positive test (median age 49 years \[IQR: 45, 53\]). Among the 176 women born before 1965 (baby-boomer cohort), 30.1% (*n* = 53) reported not having a previous HCV test, and among the 93 HCV positive women in this age cohort, 31.2% (*n* = 29) were not aware of their anti-HCV status. Among 47 women who reported a history of IDU, 12.8% (*n* = 6) reported no previous HCV test, and among the 32 HCV positive women with a history of this exposure, 16% (*n* = 5) were not aware of their positive status. Women who were anti-HCV positive but had no previous HCV test result compared to those who had a previous positive, reported significantly lower median monthly income in the past 6 months (\$853 \[IQR: 770, 934\] vs. \$956 \[IQR: 848, 1200\], and fewer psychiatric diagnoses (5 \[2, 10\] vs. 9 \[IQR: 6,13\]), respectively. Factors independently associated with women not knowing their HCV status (controlling for birth cohort status and IDU) included: lower income (per \$100 increase), AOR; 0.78 (95%CI: 0.65, 0.94); fewer psychiatric diagnosis (per diagnosis), AOR: 0.80 (95%CI: 0.70, 0.95); and any recent cocaine use (yes vs. no), AOR; 5.63 (95%CI: 1.16, 27.36).

Discussion {#Sec7}
==========

HCV seroprevalence was very high in this sample of homeless and unstably housed women in San Francisco with almost half (45.9%) testing positive, and among whom 61.1% were HIV coinfected. These results fill an important gap in information since the majority of studies assessing HCV infection in homeless populations have been conducted in samples that are all or predominantly male and were sampled over 15 years ago \[[@CR35]--[@CR40]\]. Nyamathi et al. \[[@CR41]\], reported 22% anti-HCV prevalence in a large sample (*n* = 884) of homeless adults in Los Angeles, yet the number of women in the sample and sex-specific prevalence were not specified. In a study of 387 clients seen at *Healthcare for the Homeless* clinics in eight cities, Strehlow et al. report that only 27.1% were women, and 21.9% of these anti-HCV positive, which is substantially lower than the prevalence reported here \[[@CR42]\]. Whether the difference is due to differences in populations is unclear (e.g., a clinic population in the Strehlow study vs. a homeless population in the current study, a higher proportion of women in the current study, or geographic differences). In particular, the over-sampling of HIV infected women in this study may account for differences seen in the overall prevalence of anti-HCV in this compared to other studies, few of which included populations with HIV infection. However, the prevalence of anti-HCV among HIV-negative women participating in the current study was 37% (44 of 119 women), which is still higher than that reported in prior studies. We did not measure HCV RNA in this study, however based on other studies \[[@CR43]\], including the National Health and Nutrition Examination Survey (NHANES) \[[@CR10]\] showing that 75 to 82% of anti-HCV positive persons remain viremic, we estimate that 34.5 to 37.8% of women had chronic disease. This is potentially underestimated since some HIV-positive women may not have had detectable anti-HCV \[[@CR44]\]. Due to their age and risk profile, there is a high probability that women in this study have been infected for decades, and thus many likely already have significant liver disease as well as other associated extra-hepatic comorbidities in addition to reduced quality of life \[[@CR45], [@CR46]\]. HIV/HCV coinfection among women in particular confers a significantly greater risk of disease compared to men suggesting that there is a sex differential in the role of immune suppression \[[@CR47]\]. In a recent study (among a similarly aged population, median age 46 years), researchers found that HCV/HIV coinfected women with low CD4 counts had almost 10 times the risk of liver disease progression compared to monoinfected women, and coinfected men had 2.86 times the risk compared to monoinfected men. Results presented here, in combination with prior studies, suggest the possibility of unrecognized but substantial liver-related morbidity among homeless and unstably housed women. As with all studies and programs providing screening, referrals for further assessment for chronic infection and liver disease should be part of clinical follow up in this population.

Over two-thirds (72%) of women in this study were born before 1965, i.e., the 'baby-boomer' cohort. Not surprisingly, they, as well as those with a history of IDU, had significantly higher independent odds of HCV exposure compared to younger women and those with no IDU history \[[@CR10], [@CR39]\], reinforcing the current recommendations for HCV screening in these groups. Homeless women are a key medically and socially challenged population, who experience significant health disparities. While a substantive proportion of women in this sample were undiagnosed, including 30% of women in the baby-boomer cohort and 12.8% of women with a history of injecting, these proportions are lower than those seen in the general population where up to 50% of infected persons are not aware of infection status. In combination with the San Francisco Department of Public Health's Homeless Outreach Team, the San Francisco Mayor's Office has a dedicated HCV task force, and significant services targeting homeless populations (e.g., The Housing, Partnerships, Opportunity and Engagement Program \[<http://www.sfmayor.org/>\]), all of which may contribute to the higher testing rate. We observed that women who had lower income, fewer psychiatric diagnoses, and who had recently used cocaine were more likely to be unaware of their HCV status. These associations with income and psychiatric diagnoses suggest a need to expand HCV testing in homeless women overall, as both economic and psychiatric status may be tenuous. While associations between cocaine use and HCV are mixed \[[@CR48]\] this exposure may be a proxy for higher risk exposures and thus patients who report this could benefit from HCV testing \[[@CR49]\]. A large proportion of women overall report seeing a primary care provider recently, which also presents an opportunity for HCV screening. Finally, a higher proportion of HCV monoinfected women were unaware of their infection suggesting that those receiving HIV care were more likely to be tested for HCV. However, given that HCV screening in HIV-positive populations has been recommended since 2002 \[[@CR50]\], it is surprising to find that more than a quarter (26.4%) of HIV/HCV coinfected women were unaware of their HCV status.

Unlike other studies we did not find associations between race/ethnicity, alcohol use, or sexual risk factors and HCV serostatus \[[@CR41], [@CR42]\], which may be due to less heterogeneity in risk within this population composed entirely of homeless and unstably housed women and oversampled for HIV. Our cut-offs for heavy and binge drinking may be overly conservative and could obscure higher levels of alcohol use. The positive association between number of psychiatric diagnoses and HCV exposure extends results from prior studies. For instance, Nyamathi et al. \[[@CR41]\], reported elevated HCV among women with a history of hospitalization for mental illness. More recent reports underscore the high levels of HCV among persons with severe mental illness (17 vs. 1% in the general population) \[[@CR51], [@CR52]\]. Results presented here show for the first time that anti-HCV positivity increases additively with additional psychiatric conditions. As previously reported, the median number of co-occurring psychiatric conditions in this population is nine \[[@CR22]\], suggesting odds of HCV exposure is elevated more than two-fold times higher in comparison with populations not impacted by psychiatric conditions. It is difficult to interpret the inverse association between depression and anti-HCV status, however this effect was independent of the number of psychiatric diagnoses, hinting that there are differential impacts by diagnosis. On a positive note, women with more psychiatric diagnoses in this study were more likely to be aware of their serostatus, potentially indicating that screening was incorporated into their clinical care.

The study has limitations which should be considered when interpreting results. The analyses are cross-sectional and thus temporal and causal effects cannot be inferred; however, confirming causation is not the goal of the study. Our overall intent is to inform testing and treatment programs by describing correlates of prevalent infection in a high risk population. While the analyses are secondary, and original data were gathered for other primary research questions, the SHADOW study did have secondary goals of documenting multiple health outcomes, of which HCV exposure was one. Only women who affirmed prior STI testing were specifically asked about HCV testing, and not all study participants would regard HCV as an infection included among STIs, thus the proportion of the entire population unaware of their anti-HCV status may be underestimated. In addition, sensitive self-reported data, such as injection drug use may have been underreported, however the effect of such would be to bias excess risk estimates toward the null, thus our results in this regard are likely conservative. Major strengths of the SHADOW study were its sampling methods, which recruited a group of women experiencing unstable housing that reflected San Francisco's larger population of unstably housed women, and disparate health outcomes, including directly measured mental health conditions, thus our results are likely to have high external validity.

Conclusions {#Sec8}
===========

The recent availability of simple, safe and curative treatment for HCV offers an enormous opportunity for improving health of millions of people, especially those experiencing homelessness, a population that experiences disproportionate impact of HCV. In 2014, surveys using 'point-in-time' counts found 564,708 to 578,424 homeless adults in the U.S., and 40% are women \[[@CR53], [@CR54]\]. Almost half of women participating in the current study had antibodies to HCV (anti-HCV) and approximately one quarter were unaware of their status. At a population level, the effect curative treatment could have on this population could be substantial. As a first step to advancing this goal, screening is critical. Increased risk-based testing and linkage to care, particularly among baby boomers and women with co-occurring mental health conditions, would benefit homeless women. Interventions to increase testing in high risk groups including targeted case finding, support and training for primary care practitioners, and offering dried blood spot testing have been shown to increase testing uptake \[[@CR55]\]. Other approaches including electronic health record best practice alert and/or physician office based direct patient-solicitation could also effectively promote HCV testing in this group \[[@CR56]\]. The presence of anti-HCV is correlated with an increasing number of psychiatric conditions in this population, and augmenting mental health care and support during HCV treatment may increase successful treatment in homeless and unstably housed women.
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